- Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and tobevibart achieved undetectable HDV RNA in 88% of participants with chronic hepatitis delta (CHD) at Week 96 of...
Barchart Research What to Expect from VIR Earnings VIR Generated August 4, 2026 Current Price $9.17 EPS Estimate $$0.83 Consensus Rating Strong Buy Average Move 12.70% Vir Biotechnology: Can the Pipeline...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23....
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. “We are pleased...
- Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in “Best of EASL 2026” by EASL - Poster...
- Global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN ® dual-masked T-cell engager (TCE) VIR-5500 closed and first patient dosed in Phase 1 dose-expansion...
Barchart Research What to Expect from VIR Earnings VIR Generated May 5, 2026 Current Price $10.01 EPS Estimate $$-0.01 Consensus Rating Strong Buy Average Move 13.11% Can Vir Biotechnology's Hepatitis...
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 Healthcare...
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results...